|
Market Closed -
Nasdaq
00:00:00 19/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 2.390 USD | +3.46% |
|
+8.64% | -55.49% |
Company Valuation: Compass Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 309 | 633.5 | 198.8 | 199.5 | 955.1 | 430.4 | - | - |
| Change | - | 105.02% | -68.61% | 0.34% | 378.75% | -54.94% | - | - |
| Enterprise Value (EV) 1 | 309 | 633.5 | 198.8 | 72.78 | 955.1 | 280.4 | 297.4 | 314.4 |
| Change | - | 105.02% | -68.61% | -63.39% | 1,212.3% | -70.64% | 6.06% | 5.72% |
| P/E | -2.42x | -13.6x | -4.73x | -4.03x | -12.8x | -4.79x | -4.39x | -11.6x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.2x | 0.4x | -0.44x | -0.8x | -0.3x | -0.49x | 0.2x |
| Capitalization / Revenue | - | - | - | 235x | - | - | 19.2x | 3.45x |
| EV / Revenue | - | - | - | 85.6x | - | - | 13.3x | 2.52x |
| EV / EBITDA | -3.8x | -15.5x | -4x | -1.3x | -13.2x | -2.8x | -2.78x | -3.06x |
| EV / EBIT | -3.77x | -15.2x | -3.95x | -1.29x | -13.1x | -2.86x | -2.73x | -6.9x |
| EV / FCF | -14.3x | - | - | -1.62x | -19.4x | -3.05x | -3.35x | -10.5x |
| FCF Yield | -6.98% | - | - | -61.7% | -5.15% | -32.8% | -29.9% | -9.54% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.31 | -0.37 | -0.33 | -0.36 | -0.42 | -0.4993 | -0.5443 | -0.2062 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 0.85 | - | - | 22.39 | 124.7 |
| EBITDA 1 | -81.32 | -40.87 | -49.66 | -56.04 | -72.56 | -100.2 | -107 | -102.6 |
| EBIT 1 | -81.88 | -41.66 | -50.36 | -56.62 | -72.84 | -98.14 | -108.8 | -45.55 |
| Net income 1 | -82.18 | -39.22 | -42.49 | -49.38 | -66.49 | -93.8 | -107.9 | -43.16 |
| Net Debt 1 | - | - | - | -126.7 | - | -150 | -133 | -116 |
| Reference price 2 | 3.170 | 5.030 | 1.560 | 1.450 | 5.370 | 2.390 | 2.390 | 2.390 |
| Nbr of stocks (in thousands) | 97,472 | 125,938 | 127,455 | 137,589 | 177,862 | 180,088 | - | - |
| Announcement Date | 18/03/22 | 15/03/23 | 21/03/24 | 27/02/25 | 05/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.79x | - | -2.8x | - | 430M | |
| 22.02x | 7.72x | 15.73x | 1.34% | 73.45B | |
| 36.15x | 9.26x | 28.49x | 0.04% | 62.99B | |
| -81.2x | 15.18x | -77.46x | -.--% | 28.05B | |
| 32.25x | 6.34x | 16.79x | -.--% | 25.42B | |
| -14.35x | 5.17x | -6.66x | -.--% | 23.3B | |
| 26.57x | 5.01x | 16.8x | -.--% | 19.45B | |
| 52.91x | 19.58x | 39.65x | 0.29% | 18.16B | |
| -7088.72x | 40.96x | -262.55x | -.--% | 16.53B | |
| 16.43x | 4.87x | 11.36x | -.--% | 13.16B | |
| Average | -700.27x | 12.68x | -22.07x | 0.19% | 28.1B | |
| Weighted average by Cap. | -403.58x | 10.88x | -7.46x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CMPX Stock
- Valuation Compass Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
